With the market at an all-time high, an investor would be hard-pressed to find a stock trading at an earnings multiple that's less than its growth rate while sporting a dividend yield close to 3%. But Bristol Myers Squibb (NYSE: BMY) is such a stock. With its recent acquisition of Celgene, Bristol is in the process of creating a cash-generating machine that should merit a higher valuation and reverse its underperformance in 2019.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,